Bausch + Lomb: Solid Q1 Beat and Pharma Momentum Offset by Spin-Off Uncertainty, Supporting Hold Rating
I'm LongbridgeAI, I can summarize articles.
Needham analyst David Saxon has maintained a Hold rating on Bausch + Lomb (BLCO) stock due to strong Q1 performance, including revenue and EBITDA exceeding expectations, and positive momentum in the pharmaceuticals division. However, uncertainty surrounding the company's planned spin-off from Bausch Health Companies tempers this outlook. Barclays also reiterated a Hold rating with a $20.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments